Back to top
more

Fulgent Genetics (FLGT)

(Delayed Data from NSDQ)

$20.67 USD

20.67
292,801

-0.11 (-0.53%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $20.68 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks

by Urmimala Biswas

We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.

Zacks Equity Research

Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (FLGT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Has FULGENT GENETIC (FLGT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (FLGT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Zacks.com featured highlights include: Amkor Tech, Daqo New Energy Corp and Fulgent Genetics

by Zacks Equity Research

Zacks.com featured highlights include: Amkor Tech, Daqo New Energy Corp and Fulgent Genetics

Zacks Equity Research

Buy These 3 Stocks With Momentum Anomaly for Higher Returns

by Zacks Equity Research

Amkor Technology (AMKR), Daqo New Energy (DQ) and Fulgent Genetics (FLGT) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

Zacks Equity Research

FULGENT GENETIC (FLGT) Moves 8% Higher: Will This Strength Last?

by Zacks Equity Research

FULGENT GENETIC (FLGT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

FULGENT GENETIC (FLGT) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 40.59% and 30.77%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?

by Zacks Equity Research

We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.

Zacks Equity Research

FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

FULGENT GENETIC (FLGT) closed at $110.38 in the latest trading session, marking a +1.55% move from the prior day.

Zacks Equity Research

Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (FLGT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for February 24th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 24th

Zacks Equity Research

FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

FULGENT GENETIC (FLGT) closed at $170.98 in the latest trading session, marking a -0.86% move from the prior day.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for February 9th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 9th.

Zacks Equity Research

Earnings Estimates Rising for FULGENT GENETIC (FLGT): Will It Gain?

by Zacks Equity Research

FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why FULGENT GENETIC (FLGT) is a Great Choice

by Zacks Equity Research

Does FULGENT GENETIC (FLGT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

FULGENT GENETIC (FLGT) closed the most recent trading day at $70, moving +1.1% from the previous trading session.

Zacks Equity Research

FULGENT GENETIC (FLGT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

FULGENT GENETIC (FLGT) closed at $69.07 in the latest trading session, marking a -1.1% move from the prior day.

Zacks Equity Research

Fulgent Genetics' (FLGT) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Fulgent Genetics (FLGT).

Urmimala Biswas headshot

4 MedTech Stocks Up More Than 100% in 2020 With Room to Run

by Urmimala Biswas

We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.

Zacks Equity Research

Zacks.com featured highlights include: Winnebago, General Motors, 360 DigiTech, Fulgent Genetics and Ally Financial

by Zacks Equity Research

Zacks.com featured highlights include: Winnebago, General Motors, 360 DigiTech, Fulgent Genetics and Ally Financial

Rimmi Singhi headshot

5 High Earnings Yield Bets Amid an Uncertain Santa Rally

by Rimmi Singhi

Check out these five high earnings yield stocks that can make you rich, irrespective of the Santa rally or a year-end pullback.

Zacks Equity Research

Health Catalyst (HCAT) Catches Eye: Stock Jumps 5.1%

by Zacks Equity Research

Health Catalyst (HCAT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic

Zacks Equity Research

3 MedTech Growth Stocks With Solid Prospects for 2021

by Zacks Equity Research

Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for December 10th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 10th